GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CV Sciences Inc (OTCPK:CVSI) » Definitions » Cash, Cash Equivalents, Marketable Securities

CV Sciences (CV Sciences) Cash, Cash Equivalents, Marketable Securities : $0.66 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is CV Sciences Cash, Cash Equivalents, Marketable Securities?

CV Sciences's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($1.64 Mil) to Dec. 2023 ($1.32 Mil) but then stayed the same from Dec. 2023 ($1.32 Mil) to Mar. 2024 ($0.66 Mil).

CV Sciences's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($1.38 Mil) to Dec. 2022 ($0.61 Mil) but then increased from Dec. 2022 ($0.61 Mil) to Dec. 2023 ($1.32 Mil).


CV Sciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for CV Sciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CV Sciences Cash, Cash Equivalents, Marketable Securities Chart

CV Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.11 4.02 1.38 0.61 1.32

CV Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 1.69 1.64 1.32 0.66

CV Sciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


CV Sciences  (OTCPK:CVSI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


CV Sciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of CV Sciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


CV Sciences (CV Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CV Sciences Inc (OTCPK:CVSI) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126
CV Sciences Inc is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). The company also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based novel therapeutics.
Executives
William Mccorkle director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Corroon James Michael Jr. director 9530 PADGETT STREET, SUITE 107, SAN DIEGO CA 92126
Maroon Joseph C Md director 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mona Michael Joseph Jr director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Paul Blake director 145 BRANDYWINE PKWY, WEST CHESTER PA 19380
Douglas Jesse Mackay officer: Sr VP Scientific/Regulatory 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Joseph D Dowling officer: Chief Financial Officer 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Joerg Grasser officer: CFO 2688 SOUTH RAINBOW BLVD STE B, LAS VEGAS NV 89146
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Terri F Graham director C/O JACK IN THE BOX INC, 9330 BALVOA AVE, SAN DIEGO CA 92123
Stephen Martin Schmitz director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Gary Sligar director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
James A Mcnulty director C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Larry Phillip Raskin director 1630 FUNNY CIDE DRIVE, WAXHAW NC 28173
Mackay Ventures Inc. other: Member 10% holding group 6325 S. JONES BOULEVARD #500, LAS VEGAS NV 89118

CV Sciences (CV Sciences) Headlines

From GuruFocus

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022

By GuruFocusNews GuruFocusNews 05-22-2022

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022

By GuruFocusNews GuruFocusNews 06-21-2022

CV Sciences, Inc. Extinguishes Convertible Debt

By PRNewswire PRNewswire 08-25-2022

CV Sciences, Inc. Announces New Distribution Agreement with GNC

By GuruFocusNews GuruFocusNews 01-05-2022

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022

By GuruFocusNews GuruFocusNews 07-01-2022

CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 2022

By GuruFocusNews GuruFocusNews 06-11-2022

CV Sciences, Inc. Appoints Haskell & White LLP as Auditor

By GuruFocusNews GuruFocusNews 11-30-2021